333 related articles for article (PubMed ID: 7511983)
21. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide.
Nakashima E; Matsushita R; Negishi H; Nomura M; Harada S; Yamamoto H; Miyamoto K; Ichimura F
J Pharm Sci; 1995 Oct; 84(10):1205-9. PubMed ID: 8801335
[TBL] [Abstract][Full Text] [Related]
22. Circumvention of multidrug resistance in P388 murine leukemia cells by a novel inhibitor of cyclic AMP-dependent protein kinase, H-87.
Miyamoto K; Wakusawa S; Nakamura S; Koshiura R; Otsuka K; Naito K; Hagiwara M; Hidaka H
Cancer Lett; 1990 May; 51(1):37-42. PubMed ID: 2337896
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells.
Radel S; Fredericks W; Mayhew E; Baker R
Cancer Chemother Pharmacol; 1990; 25(4):241-6. PubMed ID: 1967228
[TBL] [Abstract][Full Text] [Related]
24. Differential modulation of P-glycoprotein transport by protein kinase inhibition.
Bates SE; Lee JS; Dickstein B; Spolyar M; Fojo AT
Biochemistry; 1993 Sep; 32(35):9156-64. PubMed ID: 7690250
[TBL] [Abstract][Full Text] [Related]
25. Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.
Mayer LD; Lim KT; Hartley D
J Exp Ther Oncol; 2002; 2(2):107-20. PubMed ID: 12415627
[TBL] [Abstract][Full Text] [Related]
26. Possible coexistence of two independent mechanisms contributing to anthracycline resistance in leukaemia P388 cells.
Soto F; Planells-Cases R; Canaves JM; Ferrer-Montiel AV; Aleu J; Gamarro F; Castanys S; Gonzalez-Ros JM; Ferragut JA
Eur J Cancer; 1993; 29A(15):2144-50. PubMed ID: 7905276
[TBL] [Abstract][Full Text] [Related]
27. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin.
Nagasawa K; Natazuka T; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jan; 19(1):100-5. PubMed ID: 8820920
[TBL] [Abstract][Full Text] [Related]
28. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.
Utz I; Hofer S; Regenass U; Hilbe W; Thaler J; Grunicke H; Hofmann J
Int J Cancer; 1994 Apr; 57(1):104-10. PubMed ID: 7908658
[TBL] [Abstract][Full Text] [Related]
29. Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart.
Rosati A; Decorti G; Klugmann FB; Candussio L; Granzotto M; Melato M; Giraldi T
Anticancer Res; 2000; 20(5B):3403-10. PubMed ID: 11131640
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
31. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Friche E; Demant EJ; Sehested M; Nissen NI
Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
[TBL] [Abstract][Full Text] [Related]
32. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
[TBL] [Abstract][Full Text] [Related]
33. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
[TBL] [Abstract][Full Text] [Related]
34. Overcoming of vinblastine resistance by isoquinolinesulfonamide compounds in adriamycin-resistant leukemia cells.
Wakusawa S; Nakamura S; Tajima K; Miyamoto K; Hagiwara M; Hidaka H
Mol Pharmacol; 1992 Jun; 41(6):1034-8. PubMed ID: 1614407
[TBL] [Abstract][Full Text] [Related]
35. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
[TBL] [Abstract][Full Text] [Related]
36. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.
Ramu A; Fuks Z; Gatt S; Glaubiger D
Cancer Res; 1984 Jan; 44(1):144-8. PubMed ID: 6690032
[TBL] [Abstract][Full Text] [Related]
37. Reversal of vinblastine resistance by a new staurosporine derivative, NA-382, in P388/ADR cells.
Miyamoto K; Wakusawa S; Inoko K; Takagi K; Koyama M
Cancer Lett; 1992 Jun; 64(2):177-83. PubMed ID: 1351792
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
[TBL] [Abstract][Full Text] [Related]
39. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
Politi PM; Sinha BK
Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
[TBL] [Abstract][Full Text] [Related]
40. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity.
Conseil G; Perez-Victoria JM; Jault JM; Gamarro F; Goffeau A; Hofmann J; Di Pietro A
Biochemistry; 2001 Feb; 40(8):2564-71. PubMed ID: 11327879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
